

Clinical Observation on 30 Patients with Primary Hepatic Carcinoma in the Middle and Advanced Stage Treated with *Jianpi Rougan Fang* (健脾柔肝方) Combined with Tegafur Gimeracil Oteracil Potassium Capsule

SHI Guojun, YE Xingtao, LU Ning, DONG Jing, SHI Hang, SHAN Guangzhi

(Chinese Medical Hospital of Ningbo City, Zhejiang, 315010)

ABSTRACT Objective To observe the clinical effects of *Jianpi Rougan Fang* combined with Tegafur Gimeracil Oteracil Potassium capsule in the treatment of 30 patients with primary hepatic carcinoma in the middle and advanced stage. **Methods** Fifty-five patients with primary hepatic carcinoma in the middle and advanced stage were divided into the control group (25 cases) and the treatment group (30 cases). Both groups took Tegafur Gimeracil Oteracil Potassium capsule for chemotherapy. The treatment group also took modified *Jianpi Rougan Fang*, one dose daily. Twenty-one days were considered as a treatment course, and both groups were given four treatment courses in all. Scores of Chinese medical symptom, quality of life, and size of hepatic tumors in two groups were compared before and after the treatment. The clinical effects, curative effects of Chinese medical symptom, quality of life, and toxic and side effects were evaluated after the treatment. The survival situation within one year after the treatment was also followed-up. **Results** The objective response rate of clinical effects and the clinical beneficial rate were 30.00% and 83.33% in the treatment group, but 28.00% and 76.00% in the control group, respectively, with no significant difference between the two groups ($P > 0.05$). In the treatment group, the total effective rates of curative effects of Chinese medical symptom and quality of life were significantly higher than those in the control group ($P < 0.05$). After the treatment, scores of symptoms in the treatment group were significantly lower than those before the treatment ($P < 0.05$). After the treatment, scores of poor appetite, fatigue, abdominal distension and loose stool in the treatment group were significantly lower than those in the control group ($P < 0.05$). After the treatment in both groups, KPS score were significantly higher and the tumor size significantly decreased than those before the treatment ($P < 0.05$). After the treatment, score of the quality of life in the treatment group was significantly higher than that in the control group ($P < 0.05$). In the treatment group, cases with leukopenia, thrombocytopenia, stomatitis, and peripheral neurovirulence were significantly less than those in the control group ($P < 0.05$). There was statistically significant difference in survival curve between the two groups ($P < 0.05$). **Conclusion** *Jianpi Rougan Fang* combined with Tegafur Gimeracil Oteracil Potassium capsule may improve clinical symptoms and quality of life, reduce toxic and side effects of chemotherapy, and prolong survival time of patients with primary hepatic carcinoma in the middle and advanced stage.

Keywords primary hepatic carcinoma; *Jianpi Rougan Fang* (健脾柔肝方); Tegafur Gimeracil Oteracil Potassium capsule; quality of life; toxic and side effects

(收稿日期: 2015-07-26; 修回日期: 2015-10-11)

编辑: 王利芬

第七届中国中医妇科学术大会通知 (第一轮征文)

为促进国内外从事中医妇科领域学者进行学术交流, 加强中医药国际化传播, 共同提高中医药诊治妇科疾病水平。由世界中医药学会联合会主办, 世界中医药学会联合会妇科专业委员会承办, 湖南安邦制药有限公司协办的“第七届中国中医妇科学术大会”, 以妇科疑难病诊疗研究为主题, 拟定于 2016 年 9 月在昆明市举行, 届时将举办妇科疑难病诊治高级研讨班, 并设“安邦杯”妇科养血颗粒有奖征文活动, 评选优秀学术论文。同时邀请国内外著名妇科专家进行专题学术讲座及大会学术交流。现将有关事宜通知如下:

一、征文内容

1. 名老中医对妇科疑难病的中医诊疗方案及学术经验; 2. 妇科疑难病诊治的中医优势及其特色疗法; 3. 新技术、新疗法在诊治妇科疑难病中应用及最新研究进展; 4. 历代医家诊治妇科疑难病经验挖掘与文献整理; 5. 妇科养血颗粒组方研究、药理作用及临床应用; 6. 妇科养血颗粒药效基础及安全性观察; 7. 妇科养血颗粒深层次开发思路及远景规划。

二、征文要求

1. 论文要求未在公开杂志发表, 主题鲜明, 论据充分, 内容详实, 文责自负。2. 中英文论文均以 word 格式投稿, 全文篇幅在 4000 字左右。3. 所有论文一律采用电子投稿 (fkfh189@163.com)。4. 投稿截止日期: 2016 年 7 月 31 日。

三、会议负责人及联系方式 刘丹卓 13787132521 fkfh189@163.com